ASTRAZEN

Pharmaceuticals & Drugs

₹4413.95

0.00 (0.00%)

Market Cap	11,454 Cr		EPS	53.2		High	4596.2
Stock P/E	86.1		Net Profit Margin	18.2		Low	4382.7

The current prices are delayed, login to your account to see live prices.

Performance

Today’s Low

Today’s High

4382.7

4596.2

52W Low

52W High

2911

4640

Open Price	4589	Volume	38
Prev. Close	4593.1

Fundamentals

Market Cap	11,454 Cr	ROE	18.1%
P/E Ratio(TTM)	86.1	EPS(TTM)	0.0
P/B Ratio	17.9	Dividend Yield	0.3%
Industry P/E	40.6	Book Value	256.0
		Face Value	2.0

About the Company

Astrazeneca Pharma India (AZPIL) incorporated on 11 July, 1979 is engaged in the business of manufacturing and marketing pharmaceutical products in healthcare segments namely gastrointestinal, cardiovascular, cancer, respiratory, neurosciences and infection. The company has an innovative portfolio in crucial areas of healthcare including cardiovascular, renal & metabolic diseases, oncology and respiratory. AstraZeneca Pharma India is a subsidiary of AstraZeneca Pharmaceuticals AB, Sweden, which is an indirect subsidiary of AstraZeneca PLC.

The company’s Global Technology Centre (GTC) in Chennai, is its primary insourced IT facility delivering significant value to the business through an end-to-end, integrated IT service delivery mode. The centre was set up in September 2014 in Chennai, Tamil Nadu, India with the mandate to deliver best in class IT service for the global business.

The company launched its R&D Bangalore in 2017 to support AstraZeneca’s global established medicines portfolio. The R&D Bangalore team provides support across a range of therapy areas, including oncology, respiratory and cardiovascular and metabolic diseases, with a focus on AstraZeneca’s mature brands which are used by patients around the world.

The Global Business Services (GBS), which now houses Global Commercial Operations (GCO), was set up in Chennai in 2017 and has driven efficiency across content management, multichannel marketing and analytics and reporting. GCO Global supports E2E commercial content management to markets - from creation, production, review, process, publishing and reporting. GCO helps multiple markets to avoid duplication of content leading to faster launches and cost savings.

Business area of the company

The Company is engaged in the business of manufacture, distribution and marketing of life-changing medicines in crucial areas of healthcare including oncology, cardiovascular, diabetes, renal, metabolic and respiratory.

Core Therapy Areas

Cardiovascular
Oncology
Respiratory

Milestones and achievements

1979: Astra IDL formation.
1982: Astra factory foundation.
1992: Launch of Cerviprime, Plendil, Ramace, Rhinocort and Imdur.
2001: Merger of Astra & Zeneca in 1999 globally, formed ‘AstraZeneca’ name in India in 2001.
2015: Launch of Forxiga.
2017: Launch of Tagrisso.
2018: Launch of Xigduo XR.
2018: Launch of first Metabolic Centre of Excellence in India.
2019: Launch of Lynparza.
2020: AstraZeneca India launches Qtern.